Duloxetine recalled due to presence of nitrosamine

FDA issued a Class II recall for the antidepressant duloxetine, manufactured by Towa Pharmaceutical Europe, after detecting nitrosamine impurities, which are known carcinogens. The recall affects 7,107 bottles with an expiration date of December 2024. FDA urges consumers with affected products to contact their healthcare provider or return them to the pharmacy.